News Updates
More Articles
- Benefits of Integrating Patient Engagement with Diversity, Equity, and Inclusion in New Medical Product Development: A Call for Action
- Drug Shortages in the Global South: A Proposed Parallel Tech and Reg Transfer Framework
- Fair Pay for Patient Engagement: Navigating the Evolving Landscape of Remuneration
- Industry’s Window to Express Interest in Africa Continental Product Evaluation Pilot Closes End of February 2024
- Accelerating Adoption of eLabeling in Singapore: One Company’s Journey
Ensuring Data Privacy in EU Pharmacovigilance
All Marketing Authorization Holders (MAHs) in the EU must comply with post-marketing pharmacovigilance (PV) requirements, including reporting of adverse events (AEs), and simultaneously ensure that personal data are processed only where necessary and only where the parties involved assess this necessity at every stage of the PV process.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!